Skip to main content
Erschienen in: Diseases of the Colon & Rectum 11/2007

01.11.2007 | Original Contributions

Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis?

verfasst von: Stefanie J. Schluender, M.D., Andrew Ippoliti, M.D., Marla Dubinsky, M.D., Eric A. Vasiliauskas, M.D., Konstantinos A. Papadakis, M.D., Ling Mei, M.D., Stephan R. Targan, M.D., Phillip R. Fleshner, M.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Since infliximab has been approved for treatment of patients with refractory ulcerative colitis, surgeons will be increasingly faced with operating on patients who have failed therapy with this potent immunosuppressant. This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy.

Methods

The charts of patients undergoing ileal pouch-anal anastomosis or subtotal colectomy for refractory ulcerative colitis during the five-year period ending October 2005 were reviewed. Postoperative medical and surgical complications were assessed.

Results

Seventeen patients had failed infliximab treatment and 134 patients were never treated with infliximab. Ileal pouch-anal anastomosis was performed in 112 patients (74 percent) and subtotal colectomy in 39 patients (36 percent). There were no deaths. Postoperative complications were observed in 43 patients (28 percent), with no significant difference observed between infliximab-treated (37 percent) and infliximab-untreated patients (27 percent). Of 61 patients (40 percent) treated with preoperative cyclosporine A, 5 patients also had been treated with infliximab. The infliximab and cyclosporine A-treated patient group had an 80 percent complication rate, significantly higher than the 29 percent complication rate noted in the cyclosporine A only-treated group (P--.04).

Conclusions

Although preoperative treatment with infliximab alone does not significantly increase the incidence of postoperative complications, using both inflixiamb and cyclosporine A before colectomy in refractory ulcerative colitis is associated with high surgical morbidity.
Literatur
1.
Zurück zum Zitat ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002;50:206-1.CrossRefPubMed ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002;50:206-1.CrossRefPubMed
2.
Zurück zum Zitat Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029-5.CrossRefPubMed Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029-5.CrossRefPubMed
3.
Zurück zum Zitat Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-6.CrossRefPubMed Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-6.CrossRefPubMed
4.
Zurück zum Zitat Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-7.CrossRefPubMed Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-7.CrossRefPubMed
5.
Zurück zum Zitat Brzezinski A, Armstrong L, Alvarez del Real G, Parsi M, Lashner B, Achar JP. Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn’s disease [abstract]. Gastroenterology 2002;122:A617. Brzezinski A, Armstrong L, Alvarez del Real G, Parsi M, Lashner B, Achar JP. Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn’s disease [abstract]. Gastroenterology 2002;122:A617.
6.
Zurück zum Zitat Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-3.CrossRefPubMed Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-3.CrossRefPubMed
7.
Zurück zum Zitat Marchal L, D’Haens G, Van Assche G, et al. The risk of postoperative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-4.CrossRefPubMed Marchal L, D’Haens G, Van Assche G, et al. The risk of postoperative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-4.CrossRefPubMed
8.
Zurück zum Zitat Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-0.CrossRefPubMed Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-0.CrossRefPubMed
9.
Zurück zum Zitat Ognibene S, Vasiliauskas EA, Dubinsky MC, et al. Long-term effects of cyclosporine A on morbidity after colectomy for ulcerative colitis: a word of caution [meeting abstract]. Dis Colon Rectum 2005;48:671. Ognibene S, Vasiliauskas EA, Dubinsky MC, et al. Long-term effects of cyclosporine A on morbidity after colectomy for ulcerative colitis: a word of caution [meeting abstract]. Dis Colon Rectum 2005;48:671.
10.
Zurück zum Zitat Ulich TE, del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987;139:3406-5.PubMed Ulich TE, del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987;139:3406-5.PubMed
11.
Zurück zum Zitat Sugarman B, Aggarwal B, Hass P, Figari I, Palladino M, Shepard H. Recombinant human tumor necrosis factor-alpha effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943-.CrossRefPubMed Sugarman B, Aggarwal B, Hass P, Figari I, Palladino M, Shepard H. Recombinant human tumor necrosis factor-alpha effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943-.CrossRefPubMed
12.
Zurück zum Zitat Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor (TNF-α) and a synthetic TNF-α 31-8 peptide. J Exp Med 1990;172:1749-6.CrossRefPubMed Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor (TNF-α) and a synthetic TNF-α 31-8 peptide. J Exp Med 1990;172:1749-6.CrossRefPubMed
13.
Zurück zum Zitat Albina J, Mastrofrancesco B, Vessella J, et al. HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol 2001;281:C1971-.PubMed Albina J, Mastrofrancesco B, Vessella J, et al. HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol 2001;281:C1971-.PubMed
14.
Zurück zum Zitat Lee L, Efron D, Tantry U, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Rep Reg 2000:8:547-3.CrossRef Lee L, Efron D, Tantry U, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Rep Reg 2000:8:547-3.CrossRef
15.
Zurück zum Zitat Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-.CrossRefPubMed Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-.CrossRefPubMed
16.
Zurück zum Zitat Baert FJ, D’Haens GR, Peeters M, et al. Tumor necrosis factor-alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999;116:22-.CrossRefPubMed Baert FJ, D’Haens GR, Peeters M, et al. Tumor necrosis factor-alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999;116:22-.CrossRefPubMed
17.
Zurück zum Zitat Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;345:1098-04.CrossRef Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;345:1098-04.CrossRef
18.
Zurück zum Zitat Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population-based cohort from Stockholm County. Gut 2004;53:849-3.CrossRefPubMed Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population-based cohort from Stockholm County. Gut 2004;53:849-3.CrossRefPubMed
19.
Zurück zum Zitat Keane J, Gershon S, Wise R, et al. Tuberculosis associated with infliximab, a tumor necrosis factor- α neutralizing agent. N Engl J Med 2001;345:1098-04.CrossRefPubMed Keane J, Gershon S, Wise R, et al. Tuberculosis associated with infliximab, a tumor necrosis factor- α neutralizing agent. N Engl J Med 2001;345:1098-04.CrossRefPubMed
20.
Zurück zum Zitat Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19–31.CrossRefPubMed Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19–31.CrossRefPubMed
21.
Zurück zum Zitat Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995;38:1241-.CrossRefPubMed Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995;38:1241-.CrossRefPubMed
Metadaten
Titel
Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis?
verfasst von
Stefanie J. Schluender, M.D.
Andrew Ippoliti, M.D.
Marla Dubinsky, M.D.
Eric A. Vasiliauskas, M.D.
Konstantinos A. Papadakis, M.D.
Ling Mei, M.D.
Stephan R. Targan, M.D.
Phillip R. Fleshner, M.D.
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 11/2007
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-007-9008-3

Weitere Artikel der Ausgabe 11/2007

Diseases of the Colon & Rectum 11/2007 Zur Ausgabe

Selected Abstracts

Selected Abstracts

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.